Atherosclerosis and Lipoproteins

Balance Between PGD Synthase and PGE Synthase Is a Major Determinant of Atherosclerotic Plaque Instability in Humans

Francesco Cipollone, Maria Fazia, Annalisa Iezzi, Giovanni Ciabattoni, Barbara Pini, Chiara Cuccurullo, Sante Ucchino, Francesco Spigonardo, Mariella De Luca, Cesaria Prontera, Francesco Chiarelli, Franco Cuccurullo, Andrea Mezzetti

Objective—Inducible cyclooxygenase (COX-2) catalyzes the first step in prostanoid biosynthesis and is considered a proinflammatory enzyme. COX-2 and type 1 inducible PGE synthase (mPGES-1) have a role in metalloproteinase (MMP) release leading to plaque rupture. In contrast, lipocalin-type PGD synthase (L-PGDS) has been shown to exert antiinflammatory actions. Thus, in this study we investigated whether a shift from a PGDS-oriented to a PES-oriented profile in arachidonate metabolism leads to inflammatory activation in rupture-prone plaque macrophages.

Methods and Results—Atherosclerotic plaques were obtained from 60 patients who underwent carotid endarterectomy, symptomatic (n=30) and asymptomatic (n=30) according to evidence of recent transient ischemic attack or stroke. Plaques were analyzed for COX-2, mPGES-1, L-PGDS, PPARγ, IκBα, NF-κB, and MMP-9 by immunocytochemistry, Western blot, reverse-transcriptase polymerase chain reaction, enzyme immunoassay, and zymography. Prostaglandin E2 (PGE2) pathway was significantly prevalent in symptomatic plaques, whereas PGD2 pathway was overexpressed in asymptomatic ones, associated with NF-κB inactivation and MMP-9 suppression. In vitro COX-2 inhibition in monocytes was associated with reduced MMP-9 release only when PGD2 pathway overcame PGE2 pathway.

Conclusions—These results suggest that COX-2 may have proinflammatory and antiinflammatory properties as a function of expression of downstream PGH2 isomerases, and that the switch from L-PGDS to mPGES-1 in plaque macrophages is associated with cerebral ischemic syndromes, possibly through MMP-induced plaque rupture. (Arterioscler Thromb Vasc Biol. 2004;24:1259-1265.)

Key Words: COX-2 ■ PGE synthase ■ PGD synthase ■ metalloproteinase ■ plaque rupture

There is increasing evidence that inflammation plays a central role in the cascade of events that result in plaque erosion and fissuring.1 Lesional macrophages synthesize matrix metalloproteinases (MMPs), proteolytic enzymes capable of degrading plaque constituents.2 In particular, 92 kDa gelatinase (MMP-9), which is specialized in the digestion of collagen fragments, has been critically associated with acute ischemic events in humans.3,4 The MMP-9 promoter contains a clearly defined NF-κB binding site, and NF-κB is therefore one of the transduction pathways that ultimately regulate MMP-9 secretion.5 Furthermore, it has been shown that secretion of MMP-9 by macrophages in human atherosclerotic plaques occurs through a prostaglandin (PG) E2-dependent mechanism.3 PGE2 biosynthesis is influenced by changes in cyclooxygenase (COX) and PGE synthase (PGS) expression.3 Two isoforms of COX and 3 of PGS have been identified, referred to as COX-1 and COX-2 and cytosolic PGS (cPGS) and type 1 and type 2 membrane-bound PGS (mPGES-1 and mPGES-2), respectively. Whereas COX-1 and cPGS are constitutively expressed, COX-2 and mPGS-1 are coregulated in nucleated cells in response to growth factors and cytokines, suggesting that these enzymes are involved in the generation of prostaglandins in inflammatory diseases.3,6 Consistent with the hypothesis of COX-2 and mPGES-1 contributing to the clinical instability of plaques, we recently reported enhanced MMP-9 production by macrophages in symptomatic plaques caused by the enhancement in PGE2 synthesis as a result of the induction of the functionally coupled COX-2/mPGES-1.3

However, prostaglandins also possess antiinflammatory properties. In fact, circulating PGD synthase (PGDS) has been recently identified as a protective factor in reducing the incidence of restenosis in patients undergoing percutaneous transluminal coronary angioplasty. Furthermore, it has been reported that the PGDS derivative 15-deoxy-\(\Delta^{12,14}\)-PGJ2 (15d-PGJ), is a potent inhibitor of NF-\(\kappa\)B and I\(\kappa\)K and may also exert several antiinflammatory effects through mechanisms involving peroxisome proliferator activated receptor (PPAR\(\gamma\)) activation. It is important to acknowledge that staining for 15-deoxy-\(\Delta^{12,14}\)-PGJ2 has been recently reported in macrophages in human atherosclerotic plaques, together with COX-2 expression.

There are 2 distinct isoforms of PGDS. One is the hematopoietic PGDS (H-PGDS); the other is the lipocalin-type PGDS (L-PGDS), whose expression has been recently reported in human atherosclerotic plaques. Worth attention is the fact that proinflammatory stimuli such as tumor necrosis factor alpha (TNF\(\alpha\)) found within atheromatosclerotic lesions reduced PGD\(\_2\) synthesis and increased PGE\(\_2\) release, whereas glucocorticoids may have opposing effects. Thus, the relative abundance of a specific prostanoid is the result of the expression and activity of its specific isomerase, and the predominant expression of mPGES-1 over L-PGDS might lead to increased inflammation and plaque disruption (Figure 1).

This evidence prompted us to investigate whether a shift in the isomerase activity, in the sense of a prevalent biosynthesis of PGE\(\_2\), could lead, in turn, to enhanced inflammatory activation and MMP-9 production in macrophages of rupture-prone plaques (Figure 1).

### Methods

#### Patients

Between February and November 2001, we studied 60 of 96 consecutive surgical inpatients enlisted to undergo carotid endarterectomy for high-grade (\(\geq 70\%\)) internal carotid artery stenosis; these patients were not previously included in other clinical studies. Recruitment was completed when 2 predetermined equal groups of 30 patients according to clinical evidence of plaque instability were achieved. The first group included 30 patients who presented with transient ischemic attack or ischemic stroke (symptomatic patients). The second group included 30 patients who had an asymptomatic carotid stenosis (asymptomatic patients). Percentage of stenosis, procedural methods, concomitant therapy, and risk factors did not differ between the 2 groups (Table I, available online at http://atvb.ahajournals.org). The study was approved by local ethics review committees, and informed written consent was obtained from all patients before each examination.

#### Reagents

Antibodies anti-human \(\alpha\)-actin, anti-CD68, anti-CD3, anti-HLA-DR, anti-CD31 (Dako Corporation, Carpenteria, Calif), anti-MMP-9 (Calbiochem-Novabiochem, San Diego, Calif), anti-COX-1, anti-COX-2, anti-l-PGDS, anti-mPGES-1, anti-PPAR\(\gamma\) (Cayman Chemical, Ann Arbor, Mich), anti-I\(\kappa\)Bs (Chemicon, Temecula, Calif), and anti-p65a (Roche Biochemical, Mannheim, Germany), were used.

#### Immunohistochemistry

Plaque sections were prepared and analyzed as previously described. Analysis of immunohistochemistry was performed with a color image analysis system (AlphaEase 5.02; Alpha Innotech Corp).

#### Western Blot

Western blot analysis was performed as previously described. Bands were quantified by computer-assisted densitometry (Alpha Ease 5.02) and expressed as densitometric unit (DU).

#### SDS-PAGE Zymography

Zymographic analysis was performed as previously described. Conditioned medium of human fibrosarcoma cell line HT1080 was used as positive control with known gelatinolytic activity.

#### Reverse-Transcriptase Polymerase Chain Reaction

Reverse-transcriptase polymerase chain reaction for COX-2 was performed as previously described. The GAPDH gene was amplified as internal control. Results were quantified using computer-aided densitometric analysis (Alpha Ease 5.02).

#### Quantification of NF-\(\kappa\)B and PPAR\(\gamma\) Activity

Nuclear extracts from plaque specimens were obtained as described by Ohlsson et al. Subsequently, activated p65 was recognized by selective antibody. In addition, activated p50 and PPAR\(\gamma\) were measured by specific Trans-AM transcription factor assay kit (Active Motif).

#### Isolation and Culture of Peripheral Blood Monocytes

The isolation of peripheral monocytes from 5 healthy blood donors was assessed as previously described. Control or stimulated (LPS, 1 \(\mu\)g/mL; IL-1\(\beta\), 10 ng/mL) monocytes (20\(\times\)10⁴/mL of RPMI) were cultured in the presence of aspirin (200 \(\mu\)mol/L) and in the presence or absence of the COX-2 inhibitor NS-398 (1 to 10 \(\mu\)mol/L for 30'; Cayman), the mPGES-1 inductor TNF\(\alpha\) (10 ng/mL for 16 hours, Pепrotech Inc, Rocky Hill, NJ), and the inhibitor of mPGES-1 activity bithionine-[S, R]-sulfoximine (50 \(\mu\)mol/L for 18 hours; Sigma). PGH\(\_2\) (0.42 nM; Cayman), PGE\(\_2\) (10 \(\mu\)M; Sigma), PGD\(\_2\) (10 \(\mu\)M; Cayman), and 15d-PGJ\(\_2\) (5 \(\mu\)mol/L; Cayman) were also added to some of the cultures.
Extraction and Culture of Macrophages From Atherosclerotic Plaques

The extraction of macrophages from 5 symptomatic plaques and 5 asymptomatic plaques was assessed as previously described by de Vries et al. In some experiments, isolated cells were cultured in the presence or absence of the COX-1 inhibitor sulindac sulfide (0.1 to 10 μmol/L; Cayman) and the COX-2 inhibitor NS-398 (0.1 to 10 μmol/L). PGH₂ (0.42 nM; Cayman), PGE₂ (10⁻⁶ M; Sigma), PGD₂ (10⁻⁶ M; Cayman), 15d-PGJ₂ (5 μmol/L; Cayman), the TXA₄ agonist U46619 (10⁻⁶ M; Cayman), the PGI₂ analog carbasprostacyclin (10⁻⁶ M; Cayman), and PGF₂α (200 nM; Cayman) were also added to some of the cultures.

Enzyme Immunoassay, Enzyme-Linked Immunosorbent Assay, and Radioimmunoassay Determinations

Plaque content and in vitro release of PGE₂ (from plaque macrophages), PGD₂ (as its stable methyl oximes), and MMP-9 were measured by enzyme immunoassay (Cayman for PGs, Amersham for MMP-9). In vitro release of PGE₂ from blood monocytes was measured by radioimmunoassay. Plaque content and in vitro release of 15d-PGJ₂ was measured by specific enzyme immunoassay. In this assay, the cross-reactivity for a number of related eicosanoid compounds were determined by dissolving the cross-reactant in the assay buffer at reactivities for a number of related eicosanoid compounds were measured in the 15d-PGJ₂ assay, and the measured 15d-PGJ₂ concentrations from 500 000 to 5 pg/mL. These samples were then determined by dissolving the cross-reactant in the assay buffer at concentrations from 500 000 to 5 pg/mL. These samples were then measured in the 15d-PGJ₂ assay, and the measured 15d-PGJ₂ concentrations at 50% B/Bo were calculated. The percent cross-reactivity was calculated by comparison with the actual concentration of cross-reactant in the sample and expressed as percentage. Using this approach, the cross-reactivity with PGD₂ was only 4.92% and, more importantly, that with other non-PGDS-dependent prostaglandins was <0.01%. Finally, cross-reactivity with arachidonic acid was <0.03%.

Statistical Analysis

For clinical data and histological examination, variables were compared by use of the χ² test. The significance of difference in enzyme expression and inflammatory cell infiltration between symptomatic and asymptomatic patients was analyzed by Student t test. Data are expressed as percentage or mean ± SD. All calculations were performed using the computer program SPSS 10.0.5.

Results

Inflammatory Cell Infiltration

Plaque area occupied by macrophages and T cells was significantly greater (P < 0.0001) in symptomatic than in asymptomatic plaques (Table I). Inflammatory cells in the symptomatic plaques were always characterized by strong expression of HLA-DR antigens, which contrasted markedly with the low expression of HLA-DR in the asymptomatic plaques.

Higher COX-2 Expression in Symptomatic Plaques

COX-2 was more abundant in symptomatic lesions (26 ± 6% versus 7 ± 3%, n = 30, P < 0.0001) (Figure 2). Western blot (Figure 3) and reverse-transcriptase polymerase chain reaction revealed higher COX-2 expression in symptomatic than in asymptomatic plaques (7128 ± 111 versus 2051 ± 353 DU for protein expression, n = 30, P < 0.0001; 8636 ± 251 versus 4633 ± 198 DU for mRNA expression, n = 30, P < 0.0001). In contrast, we did not observe any difference regarding COX-1 expression (4213 ± 85 versus 3987 ± 64 DU, n = 30, P < 0.0001) (Figures 2 and 3).

Different Expression of L-PGDS and mPGES-1 in Symptomatic Plaques

Immunohistochemistry revealed strong mPGES-1 immunoreactivity, but only very weak staining for L-PGDS in symptomatic plaques (Figure 2). In contrast, L-PGDS was the predominant isomerase in asymptomatic plaques (Figure 2). This was particularly evident when serial plaque sections were analyzed for L-PGDS and mPGES-1 (Figure 4a). Enzyme staining pattern indicates their localization in macrophages and smooth muscle cells. By quantitative image analysis, levels of mPGES-1 in symptomatic plaques significantly exceeded those of L-PGDS (21 ± 3% versus 5 ± 2%, n = 30, P < 0.0001), whereas the reverse was true in the asymptomatic plaques (4 ± 2% versus 20 ± 4%, n = 30, P < 0.0001). Furthermore, only weak L-PGDS expression was observed in symptomatic plaques by Western blot, whereas a 7-fold higher signal was demonstrated for mPGES-1 (1052 ± 110 versus 7022 ± 322 DU, n = 30, P < 0.0001) (Figure 3). On the contrary, L-PGDS turned out to be the principal isomerase in asymptomatic plaques (5842 ± 128 versus 1223 ± 142 DU, n = 30, P < 0.0001) (Figure 3). However, a direct and accurate comparison of the levels of L-PGDS and mPGES-1 may be limited by variable antibody affinities. Thus, we confirmed results concerning mPGES-1/L-PGDS expression also by enzyme immunoassay measurements of the plaque content of their metabolites. In fact, PGE₂ was...
present in a higher amount (265±19 ng/mg tissue, mean±SD, n=30) with respect to PGD2 (211±25 ng/mg tissue, mean±SD, n=30; P<0.0001) and 15d-PGJ2 (71±11 pg/mg tissue, mean±SD, n=30, P<0.0001) in symptomatic plaques, whereas PGD2 (211±25 ng/mg tissue, mean±SD, n=30) overcame PGE2 (41±8 ng/mg tissue, mean±SD, n=30; P<0.0001) and 15d-PGJ2 (71±11 pg/mg tissue, mean±SD, n=30, P<0.0001) in asymptomatic plaques.

Plaque Expression of MMP-9
Staining for MMP-9 was significantly more abundant in the symptomatic than in the asymptomatic lesions (27±6% versus 7±2%; n=30, P<0.0001) (Figure 2). Increased MMP-9 in symptomatic plaques was also confirmed by Western blot (601±241 versus 3163±425 DU, n=30; P<0.0001) (Figure 3) and enzyme-linked immunosorbent assay (231±42 versus 56±12 ng/mg tissue, n=30; P<0.0001). Finally, zymography demonstrated that symptomatic plaques contained higher amounts of activated MMP-9 (2736±312 versus 692±221 DU, n=30; P<0.0001).

Reduced Inflammatory Status in Plaques Expressing High L-PGDS
PPARγ expression was significantly higher in asymptomatic plaques, with respect to symptomatic plaques, and showed a stable concordance with L-PGDS (6987±125 versus 2142±97 DU for protein expression, n=30, P<0.0001) (Figure 3). In particular, higher PPARγ expression constantly resulted in enhanced PPARγ activity (29±4 versus 21±3 pg/μg of nuclear extracts, n=30; P<0.0001). Similarly, IκBα expression was also significantly higher in asymptomatic plaques (5462±133 versus 1891±109 DU, n=30, P<0.0001) (Figure 3), showed a strong relationship with L-PGDS, and resulted in NF-κB inactivation as reflected by the selective analysis of activated form of p50 (15±4 versus 23±5 pg/μg of nuclear extracts, n=30; P<0.0001) and p65 (1261±142 versus 641±231 DU, n=30, P<0.0001; Figure 3).

Colocalization of COX-2, L-PGDS, mPGES-1, and MMP-9 in Macrophages of Symptomatic Plaques
In the first experiment, serial plaque sections were incubated with the primary antibodies anti-CD68, anti-COX-2, anti-L-PGDS, anti-mPGES-1, and anti-MMP-9. Within the lesion, staining always accumulated in the CD68+ macrophages in the plaque shoulder. In the second experiment, immunofluorescence double-labeling with confocal microscopy associated the expression of L-PGDS with COX-2 and mPGES-1 in CD68+ cells, both in plaque sections and in plaque-derived macrophages (Figure 4b).

COX-2 but Not COX-1 Is Implicated in the Generation of PGE2 and PGD2
Basal PGE2 and PGD2 release was analyzed in plaque-derived macrophages incubated with NS398 and sulindac sulfide. Results shown in Figure 5a clearly suggest that COX-2 but not COX-1 is involved in PGE2 and PGD2 synthesis.

MMP-9 Production in Monocytes Is Selectively Controlled by PGE2 and PGD2
To determine whether, in addition to PGE2 and PGD2, other COX-derived prostaglandins may influence MMP-9 produc-
MMP-9 Production in Monocytes Is a Function of Prevalent PGH$_2$-Isomerase

To determine whether a net balance in the isomerase activity in the sense of a mPGES-1-oriented metabolism could lead in turn to MMP-9 production and plaque instability in the setting of COX-2 overexpression, we initially examined the effect of selective mPGES-1 and L-PGDS blockade on NF-κB state and MMP-9 generation in stimulated monocytes in vitro (Figure 5c).

Discussion

In the present report, we provide evidence for the critical involvement of mPGES-1–oriented arachidonic acid metabolism in MMP-9 overexpression in human symptomatic atherosclerotic plaques. In particular, the present findings are the first, to the best of our knowledge, to: (1) provide evidence for an important antiinflammatory role of L-PGDS in human atherosclerotic lesions; and (2) relate the prevailing pathway of PGH$_2$ metabolism to an acute ischemic event often precipitated by rupture of atherosclerotic plaque.

Concomitantly lower expression of L-PGDS and higher expression of COX-2, mPGES-1, and MMP-9 were found in specimens obtained from the “culprit” carotid lesions of patients with recent transient ischemic attack or stroke compared with specimens obtained from asymptomatic patients. Activated macrophages were significantly more abundant in complicated plaques and represented the major source of functionally coupled COX-2/mPGES-1 and MMP-9. In contrast, although PGDS is predominantly expressed in macrophages, the site of inflammatory infiltration in symptomatic plaques was always characterized by low expression of L-PGDS, which contrasted markedly with the high expression of L-PGDS elsewhere in the asymptomatic plaques. Thus, these data suggest the presence of an active inflamma-
tory reaction with a PGE$_2$-dominated eicosanoid profile in symptomatic plaques. In fact, in agreement with the difference in COX-2, L-PGDS/mPGES-1, and MMP-9 staining pattern, the histological milieu of the lesions appears different with regard to cellularity, presence of foam cells, and cholesterol clefts, but not in the degree of vessel stenosis. This suggests that asymptomatic and symptomatic lesions are primarily different with regard to the inflammatory burden, and these differences in plaque behavior are likely to derive from differences in the presence of as yet uncharacterized stimuli for the selective expression of L-PGDS or mPGES-1 capable of influencing plaque stability. Notably, this hypothesis is also supported by the evidence of a PGES-prevalent eicosanoid profile in macrophages extracted from symptomatic plaques.

We have previously reported enhanced COX-2 and mPGES-1 expression in symptomatic atherosclerotic lesions.$^9$ However, this study did not provide any evidence about the real contribution of the antiinflammatory L-PGDS in the pathophysiology of plaque rupture. In fact, COX-2 is only an intermediate enzyme in the metabolic pathway of arachidonic acid, and the COX bioproduct PGH$_2$ is further metabolized by other isomerases to various prostanoids (PGE$_2$, PGD$_2$, PGF$_2\alpha$, PGI$_2$, TXA$_2$). Thus, the relative abundance of a specific prostanoid rather than another is the result of the expression and activity of its specific isomerase, and the concordant inflammatory induction of mPGES-1 with COX-2 in macrophages may lead in turn to a shift in arachidonic acid metabolism from the production of PGD$_2$ to the preferential synthesis of PGE$_2$. The existence of this mechanism has been recently demonstrated in rat peritoneal macrophages in vitro$^{21}$ but no evidence exist in human in vivo yet. Our results are consistent with the hypothesis that only the concomitant overexpression of COX-2 and mPGES-1 in the presence of low L-PGDS activity may realize the preferential pathway of arachidonate metabolism leading to increased biosynthesis of PGE$_2$-dependent MMP-9 in the setting of human atherosclerotic plaque. On the contrary, COX-2 overexpression in the presence of a PGD$_2$-dominated eicosanoid profile is associated with enhanced PPAR$\gamma$ and I$\kappa$B$\alpha$ activity, and reduced NF-$\kappa$B activity. Important to take into consideration is the fact that the L-PGDS bioproduct 15d-PGJ$_2$ binds to and activates the nuclear receptor PPAR$\gamma$. Furthermore, 15d-PGJ$_2$ is also an inhibitor of the activation of NF-$\kappa$B induced by inflammatory cytokines. These data are potentially important, because target genes of NF-$\kappa$B include MPP-9$^4$ and COX-2. In support of these evidences, both PGDI and 15d-PGJ$_2$ were able to completely revert the inflammatory status induced by mPGES-1 in monocytes in vitro in our study. Consequently, the effects of L-PGDS products on PPAR$\gamma$ and NF-$\kappa$B are consistent with a critical role for this isomerase in plaque stabilization. However, despite the fact that substantial in vitro evidence suggests that 15d-PGJ$_2$ activates PPAR$\gamma$,$^6$ and is a potent inhibitor of NF-$\kappa$B$^7$, our data seem to suggest that PGD$_2$ rather than 15d-PGJ$_2$ may be responsible for the antiinflammatory action of L-PGDS in human atherosclerotic plaques. In particular, this view is supported by the observation that the stimulatory effect of 15d-PGJ$_2$ on PPAR$\gamma$ has been observed in vitro at micromolar concentrations, whereas the quantity of 15d-PGJ$_2$ measured in atherosclerotic plaques in our study was significantly smaller and probably insufficient to influence PPAR$\gamma$ and NF-$\kappa$B activity and, perhaps, to produce any antiinflammatory effect. Thus, we believe that alternative pathways such as direct stimulation of DP receptors by PGD$_2$ and 15d-PGJ$_2$ in target cells$^{22}$ should be considered for explaining the anti-inflammatory action of L-PGDS in human atherosclerotic plaques.

The observation that the PG isomerase profile may influence the proinflammatory or antiinflammatory role of COX-2 in atherosclerotic plaques is in agreement with the recent analog demonstration in macrophages in vitro,$^{23}$ and with the observation that COX-2 overexpression, when associated with minimal PGE$_2$ synthesis and high PGD$_2$ levels, may contribute to the resolution of inflammation.$^{24}$ Thus, our results about the antiinflammatory role of COX-2 in human atherosclerotic plaques in the presence of high L-PGDS levels add new data to the recent observations that COX-2 is responsible for increased biosynthesis of the atheroprotective PGI$_2$ in the setting of atherosclerosis.$^{25,26}$ Furthermore, this study may contribute, at least in part, to explaining the controversial cardiovascular findings in animals and in humans suggesting that COX-2 inhibition may increase the incidence of cardiovascular events, and may have clinical implication for the prolonged use of selective COX-2 inhibitors in patients with coronary artery disease. In fact, COX-2 inhibition in selected patients with an active inflammatory reaction within recently symptomatic (eg, unstable) atherosclerotic plaques may be beneficial. In contrast, prolonged and widespread use of COX-2 inhibitors in unslected patients with coronary artery disease, most of which have stable, asymptomatic plaques with a low-inflammatory profile, may be detrimental and lead to progressive plaque destabilization.

Finally, L-PGDS may also contribute to the stabilization of COX-2 gene expression in human atherosclerotic plaque during persistent inflammatory stimulation. In fact, 15d-PGJ$_2$ may exert a negative autoregulatory loop on COX-2 gene in macrophages.$^{21}$ In contrast, PGE$_2$ produced by mPGES-1 may amplify COX-2 overexpression in the active inflammatory infiltrate of atherosclerotic lesions by an EP4-mediated positive feedback loop, further contributing to progressive plaque destabilization.$^{21}$

In conclusion, this study addresses the missing link between arachidonic acid metabolism and plaque instability by demonstrating the high prevalence of PGE$_2$-dominated eicosanoid profile in symptomatic atherosclerotic lesions and providing evidence that the shift between L-PGDS and mPGES-1 in activated plaque macrophages is associated with transient ischemic attack and stroke, possibly through MMP-9-induced matrix degradation promoting plaque rupture. These findings are potentially important from a fundamental standpoint, because they demonstrate the critical role of the PGDS/PGES balance in the evolution of atherosclerotic lesions. From a practical standpoint, these findings raise the possibility that drugs able to selectively remodel arachidonate metabolism in the sense that a PGDS-prevalent path-
way might provide a novel form of therapy for atherosclerotic plaque stabilization.

Acknowledgments
We are grateful to Carlo Patrono for critical reading of this manuscript.

References
1. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation*. 1994;89:36–44.
Balance Between PGD Synthase and PGE Synthase Is a Major Determinant of Atherosclerotic Plaque Instability in Humans
Francesco Cipollone, Maria Fazia, Annalisa Iezzi, Giovanni Ciabattoni, Barbara Pini, Chiara Cuccurullo, Sante Ucchino, Francesco Spigonardo, Mariella De Luca, Cesaria Prontera, Francesco Chiarelli, Franco Cuccurullo and Andrea Mezzetti

Arterioscler Thromb Vasc Biol. 2004;24:1259-1265; originally published online May 20, 2004; doi: 10.1161/01.ATV.0000133192.39901.be
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/24/7/1259

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2004/07/01/24.7.1259.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
Table I. Characteristics of Study Patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>SYMPTOMATIC (n=30)</th>
<th>ASYMPTOMATIC (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>72±2</td>
<td>72±3</td>
</tr>
<tr>
<td>Sex, M/F</td>
<td>16/14</td>
<td>15/15</td>
</tr>
<tr>
<td>Patients with, n</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recent TIA and Stroke</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Family history of IHD</td>
<td>23</td>
<td>22</td>
</tr>
<tr>
<td>Hypertension</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Diabetes</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>20</td>
<td>19</td>
</tr>
<tr>
<td>NSAID or glucocorticoid treatment</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Statin treatment</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Treatment with ACE inhibitors or AT1 receptors</td>
<td>17</td>
<td>16</td>
</tr>
<tr>
<td>Stenosis Severity, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>76±4</td>
<td>76±7</td>
</tr>
<tr>
<td>Range</td>
<td>70-91</td>
<td>70-93</td>
</tr>
<tr>
<td>Plaque ulceration, n (%)</td>
<td>18 (60)*</td>
<td>8 (26)</td>
</tr>
<tr>
<td>Intraplaque hemorrhage, n (%)</td>
<td>15 (50)</td>
<td>14 (47)</td>
</tr>
<tr>
<td>Percentage of macrophage-rich areas</td>
<td>21±7†</td>
<td>8±5</td>
</tr>
<tr>
<td>Number of T cells per mm² section area</td>
<td>74±21†</td>
<td>28±11</td>
</tr>
</tbody>
</table>

IHD = ischemic heart disease; TIA = Transient Ischemic Attack; NSAID = nonsteroidal anti-inflammatory drug.

*P<0.05; †P<0.0001.